Selective α7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3β and decreases tau phosphorylation in vivo
详细信息 查看全文
- 作者：Robert S. Bitner ; Arthur L. Nikkel ; Stella Markosyan ; Stephani Otte ; Pamela Puttfarcken ; Murali Gopalakrishnan
- 关键词：Nicotinic acetylcholine receptor ; α ; 7 agonist ; Alzheimer's disease ; GSK3β ; Tau ; Phosphorylation
- 刊名：Brain Research
- 出版年：2009
- 出版时间：10 April 2009
- 年：2009
- 卷：1265
- 期：Complete
- 页码：65-74
- 全文大小：1094 K
文摘
The α7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and has generated recent interest as a potential drug target for treating neurodegenerative disorders such as Alzheimer's disease (AD). The property of Ca2+ permeation associated with α7 nAChR agonism may lead to Ca2+-dependent intracellular signaling that contribute to the procognitive and neuroprotective effects that have been described with this pharmacology. In this study, we investigated whether α7 nAChR agonism leads to increased phosphorylation of the inhibitory regulating amino acid residue Ser-9 on GSK3β, a major kinase responsible for tau hyperphosphorylation in AD neuropathology. Immunohistochemical analysis revealed that the selective α7 agonist A-582941 increased S9-GSK3β phosphorylation in mouse cingulate cortex and hippocampus that was not observed in α7 nAChR knock-out mice. A-582941 steady state exposure through continuous (2 wk) infusion also increased S9-GSK3β phosphorylation in the hippocampus of Tg2576 (APP), as well as wild-type mice. Moreover, A-582941 continuous infusion decreased phosphorylation of tau in hippocampal CA3 Mossy fibers and spinal motoneurons in a hypothermia-induced tau hyperphosphorylation mouse model and AD double transgenic APP/tau mouse line, respectively. These studies demonstrate that inactivation of GSK3β may be associated with α7 nAChR-induced signaling leading to attenuated tau hyperphosphorylation, raising the intriguing possibility that α7 nAChR agonism may have disease modifying benefit in the treatment of tauopathies, in particular AD.